A new target for lung cancer
Aug. 16, 2018—Vanderbilt researchers have identified a new vulnerability in lung cancer — the transporter protein xCT — that may a therapeutic target for the disease.
New target for colorectal cancer
Mar. 17, 2017—Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.
Study identifies new culprit in lung cancer development
Jan. 27, 2016—A microRNA — a small piece of RNA involved in regulating gene expression — functions as an oncogene to drive the development of lung cancer, Vanderbilt University investigators have discovered.
Stomach cancer cues
Aug. 6, 2015—Vanderbilt scientists have discovered a new molecular mechanism that promotes stomach cancer development, findings that could provide new opportunities for treatment.
Key to prostate cancer resistance
Oct. 29, 2014—A combination of two types of therapy may be more effective in treating castration-resistant prostate cancer.
Growth factor blockade targets breast tumors
Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.